Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Alpha Tau Medical Ltd ( (DRTS) ).
On January 27, 2025, Alpha Tau Medical Ltd. announced positive interim results from multiple clinical trials utilizing their Alpha DaRT therapy. Key findings include significant improvements in disease control rates and overall survival for pancreatic cancer patients, along with promising results in a trial combining Alpha DaRT with pembrolizumab for head and neck squamous cell carcinoma. Regulatory approvals in the U.S. and France further support additional trials, potentially enhancing Alpha Tau’s market positioning in cancer treatment.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is a company based in Jerusalem, Israel, specializing in alpha-radiation cancer therapy. Their primary product, Alpha DaRT, is aimed at treating various forms of cancer, with a focus on improving treatment outcomes for patients with difficult-to-treat cancers.
YTD Price Performance: 30.0%
Average Trading Volume: 67,197
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $281.8M
See more data about DRTS stock on TipRanks’ Stock Analysis page.
